Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation

Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation

Introduction: The safety and benefit of the anti-CD38 monoclonal antibody daratumumab, which induces lysis of antibody-producing plasma cells in sensitized patients prior to kidney transplantation, remain to be determined. Methods: A 2-phase (1 and 2), monocentric open-label study was conducted to e...

Full description

Saved in:
Bibliographic Details
Main Authors: Caroline Pilon, Nizar Joher, Cédric Usureau, Emmanuelle Boutin, Anna Boueilh, Jean-Luc Taupin, Allan Thiolat, José L. Cohen, Vissal David Kheav, Florence Canoui-Poitrine, Maryvonnick Carmagnat, Philippe Grimbert, Marie Matignon
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Kidney International Reports
Subjects:
lymphocytes
pharmacokinetics
translational
transplantation
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924019053
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items